Indeed, targeting classical inflammatory molecules including IL-1, IL-6 and TNF have been shown to reduce the risk of diabetes and improve insulin sensitivity in some studies, although with variable effects (37–39). This evidence concerns the gene IL6 and diabetes mellitus.